# Helus Pharma (HELP) — Earnings

HELP · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/help/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Sep 30, 2025 |
| EPS actual | −$1.36 |
| EPS estimate | $0.00 |
| EPS surprise | +0.00% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Nov 13, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1833141/000183314125000043/cybininc-form6xkq22026.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/c60c2dbc-6a9d-d9a3-2fa9-0bd6b08c2c12.html) |

Helus Pharma's only quarter in the table is fiscal Q2 2026, the period that ended September 30, 2025. The company reported it on November 13, 2025, with a loss of $1.36 per share. No analyst estimate was given for the quarter, so there is no beat or miss to measure, and the table shows no revenue figure for the period.

With a single quarter on record, the earnings history here is very short. There is no year-earlier quarter for comparison, no annual total and no trend to describe. The fiscal labels also run ahead of the calendar: fiscal Q2 2026 ended in September 2025, so the company's fiscal year does not match the calendar year. Periods are easiest to compare with other sources by their end dates rather than by quarter labels alone.

No quarter after fiscal Q2 2026 has been added to the table yet, so there is no report pattern to project from. The Q2 report came 44 days after the quarter closed. The next figures added will show whether the per-share loss narrows or widens from $1.36, and whether a revenue figure or an analyst estimate appears.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Nov 13, 2025 | $0.00 | −$1.36 | 0.00% | — | — |

## Frequently Asked Questions

### When did Helus Pharma (HELP) last report earnings?

Helus Pharma last reported on Nov 13, 2025, covering fiscal Q2 2026.

### Did HELP beat earnings estimates?

Helus Pharma reported EPS of −$1.36 for Q2 2026, in line with the $0.00 consensus estimate.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).